Literature DB >> 2478784

Hemodynamic profile of the cardiotonic agent pimobendan.

J C van Meel1, W Diederen.   

Abstract

Pimobendan (UD-CG 115 BS) is a potent positive inotropic agent with vasodilatory properties. This hemodynamic profile was demonstrated in conscious rabbits chronically instrumented with Doppler flow probes. Pimobendan (10, 30, 100, and 300 micrograms/kg i.v.) increased cardiac output, stroke volume, heart rate, and mesenteric, renal, and hindquarter blood flow velocities, and decreased diastolic blood pressure. The positive inotropic effects of pimobendan and its effects on pre- and afterload were also shown in dogs with propranolol-induced depressed myocardial function. Pimobendan exhibited strong effects on stroke volume (up to 59%) and pulmonary capillary wedge pressure (up to -84%). The substance increased left ventricular (LV) dp/dtmax up to 150% and also had favorable effects on renal blood flow. Left ventricular function curves showed the usefulness of pimobendan in this acute heart failure model. Pimobendan is well absorbed and its duration of action is long. Positive inotropic effects of pimobendan were observed for 8-12 h after oral administration of 0.1-1 mg/kg to conscious dogs. It is concluded that pimobendan produces cardiovascular effects that may be useful in the treatment of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478784

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Calcium sensitising agents in heart failure.

Authors:  L Mathew; S D Katz
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

Review 2.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

3.  Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats.

Authors:  Keisuke Sugimoto; Kazutoshi Sugita; Kensuke Orito; Yoko Fujii
Journal:  Animals (Basel)       Date:  2022-04-11       Impact factor: 3.231

4.  Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.

Authors:  Masashi Mizuno; Shigeki Yamano; Shuichi Chimura; Atsushi Hirakawa; Yoshimi Takusagawa; Tamotsu Sawada; Shigeki Maetani; Arane Takahashi; Takeshi Mizuno; Kayoko Harada; Asako Shinoda; Shuhei Uchida; Junichiro Takeuchi; Takahiro Mizukoshi; Masaaki Endo; Masami Uechi
Journal:  J Vet Med Sci       Date:  2016-09-17       Impact factor: 1.267

5.  Comparison of the effects of long-term pimobendan and benazepril administration in normal cats.

Authors:  Yuichi Miyagawa; Noboru Machida; Noriko Toda; Yoshinori Tominaga; Naoyuki Takemura
Journal:  J Vet Med Sci       Date:  2016-03-14       Impact factor: 1.267

6.  Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.

Authors:  A Boswood; J Häggström; S G Gordon; G Wess; R L Stepien; M A Oyama; B W Keene; J Bonagura; K A MacDonald; M Patteson; S Smith; P R Fox; K Sanderson; R Woolley; V Szatmári; P Menaut; W M Church; M L O'Sullivan; J-P Jaudon; J-G Kresken; J Rush; K A Barrett; S L Rosenthal; A B Saunders; I Ljungvall; M Deinert; E Bomassi; A H Estrada; M J Fernandez Del Palacio; N S Moise; J A Abbott; Y Fujii; A Spier; M W Luethy; R A Santilli; M Uechi; A Tidholm; P Watson
Journal:  J Vet Intern Med       Date:  2016-09-28       Impact factor: 3.333

7.  Emergency Presentations Associated with Cardiovascular Disease in Exotic Herbivores.

Authors:  Rodney Schnellbacher; Emily E Olson; Joerg Mayer
Journal:  J Exot Pet Med       Date:  2012-11-29       Impact factor: 0.453

Review 8.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.